Taurus Oncology identifies breakthrough oncology assets originating in Asia and develops them into first- and best-in-class medicines for patients worldwide.
Asia has quietly become one of the world's most productive sources of novel therapeutics — yet many of its best assets remain under-recognized by global capital and global pharma. Taurus Oncology exists to close that gap.
We in-license or acquire differentiated oncology assets from originators across Asia and advance them through clinical development in the US and rest of world with the speed, rigor, and market fluency that global investors and strategics demand. Our filter is deliberately narrow: an asset must be able to win on the global stage.
We are drug developers, dealmakers, and company builders who have taken novel medicines from Phase 1 to FDA approval, executed transactions across the industry's largest acquirers, and built organizations from founding to scale. We bring that apparatus to bear on a single question — which innovative Asian assets deserve a global shot, and how quickly can we give them one.
Our team has successfully advanced multiple novel drugs from Phase 1 through FDA approval, supported by an expansive network of CROs, consultants, and clinical sites across the US, EU, and Asia.
Deep relationships with senior leadership at nearly every major global biopharma, and a track record of executing M&A, licensing, and partnership transactions with aggregate value exceeding $40 billion.
Well connected with top-tier institutional investors across private and public markets, with over $300 million raised from Series A through Series C.
We have built companies from founding to headcount of more than 100, and assembled boards and scientific advisory boards drawn from leaders across research, development, regulatory, and finance.
A deliberately concentrated portfolio means undivided attention per asset. We drive to clinical proof of concept with disciplined execution and early attention to CMC, translational science, and commercial positioning.
Whether you are an Asian biotech originator thinking through what comes next for a program, an investor curious about how we source and select, or a potential partner looking further downstream — we are always glad to talk. Early and informal is perfectly fine, and anything shared with us stays confidential.
20 Park Rd, Suite G #200